Last updated on February 2018

An 8-week Dose Ranging Study of CHF 718 pMDI in Asthmatic Subjects (BEAM)


Brief description of study

This is a phase II, multicenter, randomized, double-blind, placebo and active controlled dose ranging 5-arm parallel group study to identify the optimal dose of CHF 781 pMDI with respect to lung function and other clinical efficacy and safety outcomes.

After a 2 week run-in period under rescue albuterol as needed and background inhaled corticosteroid (ICS), patients will be randomized to one of the 5 study treatment groups. After randomization, patients will be assessed after 4 and 8 weeks of study treatment at the center. A follow-up phone call will be performed a week after the last visit.

During the study, daily asthma symptoms, peak expiratory flow, rescue and background medication use, and compliance with the study medication will be recorded via subject diary.

Clinical Study Identifier: TX155601

Contact Investigators or Research Sites near you

Start Over

Boris Nikolov

IMIC, Inc.
Palmetto Bay, FL USA
  Connect »